Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials

Долговременное сохранение клеточно-опосредованных и гуморальных ответов на вакцины против вируса гриппа A(H1N1)pdm09 и роль адъювантной системы AS03 у взрослых в ходе двух рандомизированных контролируемых исследований
Robbert van der Most, Frédéric Clément, Julie Willekens, Walthère Dewé, Karl Walravens, David W. Vaughn, Geert Leroux‐Roels
2017-04-26

A(H1N1)pdm09 influenza vaccinesAS03 adjuvantCell-mediated immune responseHumoral immune responseMemory B-cell responses
ABSTRACT We investigated the role of AS03 A (here AS03), an α-tocopherol oil-in-water emulsion-based adjuvant system, on the long-term persistence of humoral and cell-mediated immune responses to A(H1N1)pdm09 influenza vaccines. In two studies, a total of 261 healthy adults (≤60 years old) were randomized to receive two doses of AS03-adjuvanted vaccine containing 3.75 μg of hemagglutinin (HA) or nonadjuvanted vaccine containing 15 μg of hemagglutinin (in study A) or 3.75 μg of hemagglutinin (in study B) 21 days apart. Hemagglutination inhibition (HI) antibody, memory B-cell, and CD4 + /CD8 + T-cell responses were characterized up to 1 year following dose 1. We also assessed the effects of age and seasonal influenza vaccination history. AS03-adjuvanted (3.75 μg HA) vaccine and nonadjuvanted vaccine at 15 μg but not at 3.75 μg HA elicited HI antibody responses persisting at levels that continued to meet European licensure criteria through month 12. At month 12, the geometric mean titer for AS03-adjuvanted vaccine was similar to that for nonadjuvanted (15-μg) vaccine in study A (1:86 and 1:88, respectively) and higher than that for nonadjuvanted (3.75-μg) vaccine in study B (1:77 and 1:35, respectively). A(H1N1)pdm09-specific CD4 + T-cell and B-cell responses were stronger in AS03-adjuvanted groups and persisted only in these groups for 12 months at levels exceeding prevaccination frequencies. Advancing age and a seasonal vaccination history tended to reduce HI antibody and memory B-cell responses and, albeit less consistently, CD4 + T-cell responses. Thus, AS03 seemed to enhance the persistence of humoral and cell-mediated responses to A(H1N1)pdm09 vaccine, allowing for antigen sparing and mitigating potential negative effects of age and previous seasonal vaccination. (These studies have been registered at ClinicalTrials.gov under registration no. NCT00968539 and NCT00989287.)
1
A(H1N1)pdm09-specific CD4+ T-cell and memory B-cell responses were stronger with AS03 and remained above prevaccination levels for 12 months only in adjuvanted groups.
2
AS03-adjuvanted vaccine containing 3.75 μg HA sustained hemagglutination-inhibition antibody levels meeting European licensure criteria through month 12.
3
AS03-adjuvanted vaccine produced higher month-12 HI titers than nonadjuvanted vaccine containing 3.75 μg HA (1:77 versus 1:35).
4
At month 12, geometric mean HI titers were similar for AS03-adjuvanted 3.75-μg and nonadjuvanted 15-μg vaccines (1:86 versus 1:88).
5
Older age and previous seasonal influenza vaccination tended to reduce HI antibody and memory B-cell responses, with less consistent effects on CD4+ T-cell responses.
6
The findings indicate that AS03 improves long-term humoral and cellular immune persistence while enabling antigen sparing.

AS03-adjuvanted and nonadjuvanted A(H1N1)pdm09 influenza vaccines in healthy adults

Long-term persistence and modulation by AS03, age, and seasonal vaccination history of humoral and cell-mediated immune responses

Publication Details
Publication Date
2017-04-26
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Robbert van der Most
Frédéric Clément
Julie Willekens
Walthère Dewé
Karl Walravens
David W. Vaughn
Geert Leroux‐Roels
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%